12/3/2009

The FDA granted fast-track designation to KRX-0401, an experimental cancer drug from Aeterna Zentaris and Keryx Biopharmaceuticals. Aeterna is testing the product in a Phase II trial to treat multiple tumor types and intends to conduct a late-stage study for multiple myeloma.

Full Story:
Reuters

Related Summaries